论文信息 - Multiple upper gastrointestinal perforations in a 15-year-old patient treated with tocilizumab.

Multiple upper gastrointestinal perforations in a 15-year-old patient treated with tocilizumab.

Nicola Dalbeth, Angela Gao, Mark Roger, Anthony J. Doyle and Fiona M. McQueen Auckland Rheumatology Imaging Group, University of Auckland, Auckland, New Zealand. Accepted 23 April 2014 Correspondence to: Nicola Dalbeth, Bone and Joint Research Group, Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland 1023, New Zealand. Email: n.dalbeth@auckland.ac.nz

[1] C. Wouters,et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. , 2012, The New England journal of medicine.

[2] E. Ruderman. Overview of safety of non-biologic and biologic DMARDs. , 2012, Rheumatology.

[3] Á. Lanas,et al. Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis , 2012, Arthritis care & research.

[4] T. Kishimoto,et al. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis , 2012, Modern rheumatology.

[5] T. Gout,et al. Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review , 2011, Clinical Rheumatology.

[6] R. Alten. Tocilizumab: A Novel Humanized Anti-Interleukin 6 Receptor Antibody for the Treatment of Patients with Rheumatoid Arthritis , 2011, Therapeutic advances in musculoskeletal disease.

[7] B. Bannwarth,et al. Clinical safety of tocilizumab in rheumatoid arthritis , 2011, Expert opinion on drug safety.

[8] H. Ishikawa,et al. Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis , 2009, Clinical Rheumatology.